Ph.D. in Chemistry, University of Michigan, has worked for Syntex, Roche and CV Therapeutics with roles in drug discovery and business development.

Ph.D. in Bioengineering, UC Berkeley, 14 issued/pending US patents, PI of over $5 million NIH grants, previously co-founded or played instrumental roles at several life science companies.

Ph.D. in Chemistry, Univ. of Paris, over 20 years of scientific excellence and management leadership at top pharmas and public biotech companies. Before joining Optivia, he was Senior VP of Ipsen, heading its drug discovery, translational research and strategic research partnership operations.

Ph.D. in Medicinal Chemistry, Univ. of Florida, previously co-founded and served as the CSO of ARYx Therapeutics (NASDAQ:ARYX), has brought many compounds to clinical stage, including presently marketed drugs.

MD and FACC, a board certified physician and cardiologist previously co-founded and served as senior executives at several biotech companies, including CV Therapeutics (Acquired by Gilead) and ARYx Therapeutics (NASDAQ: ARYX), where he helped develop several successful pharmaceuticals.

Partner at Latham&Watkins, served as the corporate counsel to numerous public and private life science companies.

Partner at Mustang Ventures, a VC firm headquartered in Shanghai, previously a partner at the Walden Group and Advent Intl. and advisor to Bay City Capital and Pappas Ventures, 20 years of investment and startup experience, served as a lead investor and board member for over 25 life science and healthcare companies.

Professor of Biopharmaceutical Sciences at UC San Francisco. One of the world’s most respected researchers in pharmaceutical sciences, member of the National Academy of Sciences, founding president of American Association of Pharmaceutical Sciences (AAPS), has served as advisor to the FDA and numerous research organizations and drug discovery companies.